These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 32371763)

  • 61. [Pharmacological and clinical properties of AIMIX® combination tablets LD&HD, fixed-dose combination of irbesartan and amlodipine besilate].
    Mori M; Takahashi S
    Nihon Yakurigaku Zasshi; 2013 Jul; 142(1):39-46. PubMed ID: 23842227
    [No Abstract]   [Full Text] [Related]  

  • 62. Side Effects of Frequently Used Antihypertensive Drugs on Wound Healing in vitro.
    Stuermer EK; Besser M; Terberger N; Bachmann HS; Severing AL
    Skin Pharmacol Physiol; 2019; 32(3):162-172. PubMed ID: 31018213
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Valsartan/hydrochlorothiazide.
    Langtry HD; McClellan KJ
    Drugs; 1999 May; 57(5):751-5; discussion 756-8. PubMed ID: 10353300
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Ramipril + amlodipine and ramipril + hydrochlorothiazide fixed-dose combinations in relation to patient adherence.
    Simonyi G; Ferenci T; Alföldi S; Farsang C
    J Int Med Res; 2016 Oct; 44(5):1087-1091. PubMed ID: 27435392
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Tribenzor for hypertension.
    Med Lett Drugs Ther; 2010 Sep; 52(1346):70-1. PubMed ID: 20814402
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A comparison of the effects of fixed dose vs. single-agent combinations on 24-h blood pressure variability.
    Ulusoy S; Ozkan G; Konca C; Kaynar K
    Hypertens Res; 2012 Nov; 35(11):1111-7. PubMed ID: 22786565
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study.
    London G; Schmieder R; Calvo C; Asmar R
    Am J Hypertens; 2006 Jan; 19(1):113-21. PubMed ID: 16461202
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The 'pyrrhic victory' of amlodipine over hydrochlorothiazide in the OLAS Study.
    Thomopoulos C; Tsioufis C; Makris T; Stefanadis C
    J Hum Hypertens; 2011 Jun; 25(6):401-2; author reply 403-4. PubMed ID: 21368776
    [No Abstract]   [Full Text] [Related]  

  • 69. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.
    Sever P
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S91-5. PubMed ID: 9331018
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial.
    Sohn IS; Kim CJ; Oh BH; Hong TJ; Park CG; Kim BS; Chung WB;
    Am J Cardiovasc Drugs; 2016 Apr; 16(2):129-38. PubMed ID: 26691333
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Valsartan/hydrochlorothiazide: a review of its use in the management of hypertension.
    Wagstaff AJ
    Drugs; 2006; 66(14):1881-901. PubMed ID: 17040120
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension.
    Fogari R; Mugellini A; Derosa G;
    J Renin Angiotensin Aldosterone Syst; 2007 Sep; 8(3):139-44. PubMed ID: 17907102
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinical pharmacokinetics of candesartan.
    Gleiter CH; Mörike KE
    Clin Pharmacokinet; 2002; 41(1):7-17. PubMed ID: 11825094
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Single-pill combination of amlodipine and valsartan in the management of hypertension.
    Flack JM; Hilkert R
    Expert Opin Pharmacother; 2009 Aug; 10(12):1979-94. PubMed ID: 19606937
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Candesartan cilexetil: an angiotensin II receptor blocker.
    Stoukides CA; McVoy HJ; Kaul AF
    Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Characterizing the time-course of antihypertensive activity and optimal dose range of fimasartan via mechanism-based population modeling.
    Bulitta JB; Paik SH; Chi YH; Kim TH; Shin S; Landersdorfer CB; Jiao Y; Yadav R; Shin BS
    Eur J Pharm Sci; 2017 Sep; 107():32-44. PubMed ID: 28599987
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations.
    Brunner HR
    Am J Hypertens; 1997 Dec; 10(12 Pt 2):311S-317S. PubMed ID: 9438775
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pharmacokinetics, tolerability, and safety of the single oral administration of AGSAV301 vs Exforge: a randomized crossover study of healthy male volunteers.
    Choi HY; Kim YH; Kim MJ; Noh YH; Lee SH; Bae KS; Lim HS
    Am J Cardiovasc Drugs; 2014 Feb; 14(1):63-72. PubMed ID: 24174172
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Simultaneous Analysis of a Combination of Anti-Hypertensive Drugs, Fimasartan, Amlodipine, and Hydrochlorothiazide, in Rats Using LC-MS/MS and Subsequent Application to Pharmacokinetic Drug Interaction with Red Ginseng Extract.
    Jeon SY; Jeon JH; Park JH; Lee J; Pang M; Choi MK; Song IS
    Toxics; 2022 Sep; 10(10):. PubMed ID: 36287856
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Glyceroniosomes for enhanced intestinal absorption of hydrochlorothiazide and lisinopril in their fixed dose combination.
    Elbasuony AR; Abdelaziz AE; Mazyed EA; El Maghraby GM
    Sci Rep; 2024 Oct; 14(1):24499. PubMed ID: 39424875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.